PMID- 21418986
OWN - NLM
STAT- MEDLINE
DCOM- 20111115
LR  - 20141120
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 91
IP  - 2
DP  - 2011 Jan 11
TI  - [Comparison of fluorescence in situ hybridization and immunohistochemistry 
      assessment for Her-2 status in breast cancer and its relationship to 
      clinicopathological characteristics].
PG  - 76-80
AB  - OBJECTIVE: To investigate the concordance and correlation between fluorescence in 
      situ hybridization (FISH) and immunohistochemistry (IHC) assessment for HER-2 
      status in breast cancer patients and analyze their relationship to clinical 
      characteristics. METHODS: A total of 128 samples of breast cancer tissue were 
      analyzed retrospectively. FISH was employed to detect the HER-2 gene 
      amplification. And the FISH findings were compared with IHC test results by 
      analyzing the concordance and correlation between two results. And their 
      relationships to the clinical characteristics were analyzed. RESULTS: The overall 
      coincidence rate of IHC and FISH was 90.6% (kappa = 0.405, P = 0.000). And the 
      discordance was mainly found in the IHC (++) group. A positive correlation was 
      found between the two results (r = 0.655, P = 0.000). The ER (estrogen receptor) 
      expression was negatively correlated with HER-2 gene amplification and the 
      expression of Her-2 protein (r = -0.300, P = 0.001; r = -0.223, P = 0.011). There 
      was a negative correlation between ER/PR status and HER-2 gene amplification (r = 
      -0.213, P = 0.016). The similar results were found in subgroup analysis. Tumor 
      grade was negatively correlated with the expression of Her-2 protein (r = -0.293, 
      P = 0.008), but not with HER-2 gene amplification (P > 0.05). CONCLUSION: IHC is 
      a preferred method to detect the Her-2 status in breast cancer. The strong 
      positive expression (+++) of HER-2 protein tested by IHC is strongly consistent 
      with HER-2 gene amplification by FISH. But HER-2 gene amplification should be 
      further detected by FISH in patients with HER-2 positive expression (+-++) in 
      order to guide the clinical diagnosis and treatment. ER, ER/PR (progesterone 
      receptor) status and tumor grade are correlated with HER-2 gene amplification 
      and/or the expression of Her-2 protein. This study helps improve the accuracy of 
      judging HER-2 gene amplification according to the clinical and pathological 
      features such as ER status and the results of IHC.
FAU - Li, Hui-Hui
AU  - Li HH
AD  - Department of Medical Oncology, Cancer Hospital (Institute), Chinese Academy of 
      Medical Sciences & Peking Union Medical College, Beijing 100021, China.
FAU - Ma, Fei
AU  - Ma F
FAU - Zeng, Xuan
AU  - Zeng X
FAU - Wang, Jia-Yu
AU  - Wang JY
FAU - Yuan, Peng
AU  - Yuan P
FAU - Fan, Ying
AU  - Fan Y
FAU - Xu, Bing-He
AU  - Xu BH
LA  - chi
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/*metabolism/*pathology
MH  - Female
MH  - Fluorescence
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Receptor, ErbB-2/*metabolism
EDAT- 2011/03/23 06:00
MHDA- 2011/11/16 06:00
CRDT- 2011/03/23 06:00
PHST- 2011/03/23 06:00 [entrez]
PHST- 2011/03/23 06:00 [pubmed]
PHST- 2011/11/16 06:00 [medline]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2011 Jan 11;91(2):76-80.